These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21885526)

  • 21. Immunosuppressive treatment for giant cell arteritis: where do we stand?
    Pipitone N; Salvarani C
    Clin Exp Rheumatol; 2015; 33(2 Suppl 89):S-5-6. PubMed ID: 26016749
    [No Abstract]   [Full Text] [Related]  

  • 22. Might tocilizumab be useful in patients with giant-cell arteritis and normal ESR?
    Fernández-Fernández FJ; Ameneiros-Lago E; Sesma P
    Swiss Med Wkly; 2012; 142():w13503. PubMed ID: 22271487
    [No Abstract]   [Full Text] [Related]  

  • 23. Anti-Interleukin-6 Antibody as Treatment for Giant Cell Arteritis.
    Joyce Liao Y
    J Neuroophthalmol; 2018 Dec; 38(4):558-560. PubMed ID: 30199508
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatments for giant cell arteritis: Meta-analysis and assessment of estimates reliability using the fragility index.
    Berti A; Cornec D; Medina Inojosa JR; Matteson EL; Murad MH
    Semin Arthritis Rheum; 2018 Aug; 48(1):77-82. PubMed ID: 29496228
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Giant cell arteritis: new concepts, treatments and the unmet need that remains.
    Coath F; Gillbert K; Griffiths B; Hall F; Kay L; Lanyon P; Luqmani R; Mackie SL; Mason JC; Mills J; Mollan S; Morgan AW; Mukhtyar C; Quick V; Watts R; Dasgupta B
    Rheumatology (Oxford); 2019 Jul; 58(7):1123-1125. PubMed ID: 30423174
    [No Abstract]   [Full Text] [Related]  

  • 26. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial.
    Seror R; Baron G; Hachulla E; Debandt M; Larroche C; Puéchal X; Maurier F; de Wazieres B; Quéméneur T; Ravaud P; Mariette X
    Ann Rheum Dis; 2014 Dec; 73(12):2074-81. PubMed ID: 23897775
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis.
    Beyer C; Axmann R; Sahinbegovic E; Distler JH; Manger B; Schett G; Zwerina J
    Ann Rheum Dis; 2011 Oct; 70(10):1874-5. PubMed ID: 21515917
    [No Abstract]   [Full Text] [Related]  

  • 28. Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis.
    Andonopoulos AP; Meimaris N; Daoussis D; Bounas A; Giannopoulos G
    Ann Rheum Dis; 2003 Nov; 62(11):1116. PubMed ID: 14583578
    [No Abstract]   [Full Text] [Related]  

  • 29. Tocilizumab for Giant Cell Arteritis-A New Giant Step in an Old Disease.
    Tamaki H; Hajj-Ali RA
    JAMA Neurol; 2018 Feb; 75(2):145-146. PubMed ID: 29255889
    [No Abstract]   [Full Text] [Related]  

  • 30. Infliximab efficiency and failure.
    Rozin AP
    Ann Rheum Dis; 2004 Jun; 63(6):751-2; author reply 752. PubMed ID: 15140791
    [No Abstract]   [Full Text] [Related]  

  • 31. Should Tocilizumab Be Used Routinely in New Patients With a Diagnosis of Giant Cell Arteritis?
    Sadun A; Gordon L
    J Neuroophthalmol; 2020 Mar; 40(1):117-121. PubMed ID: 31834197
    [No Abstract]   [Full Text] [Related]  

  • 32. The long-term use of tocilizumab in giant cell arteritis.
    Coath FL; Mukhtyar C
    Rheumatology (Oxford); 2021 Oct; 60(10):4447-4449. PubMed ID: 33956087
    [No Abstract]   [Full Text] [Related]  

  • 33. Synovial fluid IL-6 concentrations associated with positive response to tocilizumab in an RA patient with failed response to anti-TNF and rituximab.
    Wright HL; Mewar D; Bucknall RC; Edwards SW; Moots RJ
    Rheumatology (Oxford); 2015 Apr; 54(4):743-4. PubMed ID: 25667432
    [No Abstract]   [Full Text] [Related]  

  • 34. Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series.
    Adizie T; Christidis D; Dharmapaliah C; Borg F; Dasgupta B
    Int J Clin Pract; 2012 Sep; 66(9):906-9. PubMed ID: 22897467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Vasculitis].
    Fleck M; Hellmich B
    Dtsch Med Wochenschr; 2013 Jun; 138(23):1236-9. PubMed ID: 23720179
    [No Abstract]   [Full Text] [Related]  

  • 36. Interleukin 6 targeting in refractory Takayasu arteritis: serial noninvasive imaging is mandatory to monitor efficacy.
    Youngstein T; Mason JC
    J Rheumatol; 2013 Dec; 40(12):1941-4. PubMed ID: 24293617
    [No Abstract]   [Full Text] [Related]  

  • 37. [Not Available].
    Steurer J
    Praxis (Bern 1994); 2017; 106(22):1251-1252. PubMed ID: 29088969
    [No Abstract]   [Full Text] [Related]  

  • 38. Giant-cell arteritis.
    Hall JK
    Curr Opin Ophthalmol; 2008 Nov; 19(6):454-60. PubMed ID: 18854689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reply to the letter to the editor of francisco José Fernández-Fernández et al.
    Seitz M
    Swiss Med Wkly; 2012; 142():w13504. PubMed ID: 22271505
    [No Abstract]   [Full Text] [Related]  

  • 40. Interstitial lung disease in rheumatoid arthritis: response to IL-6R blockade.
    Mohr M; Jacobi AM
    Scand J Rheumatol; 2011; 40(5):400-1. PubMed ID: 21961704
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.